Multiple Sclerosis Followed by Neuromyelitis Optica Spectrum Disorder
From the National Multiple Sclerosis Society Case Conference Proceedings
Citation Manager Formats
Make Comment
See Comments

Abstract
A woman presented at age 18 years with partial myelitis and diplopia and experienced multiple subsequent relapses. Her MRI demonstrated T2 abnormalities characteristic of multiple sclerosis (MS) (white matter ovoid lesions and Dawson fingers), and CSF demonstrated an elevated IgG index and oligoclonal bands restricted to the CSF. Diagnosed with clinically definite relapsing-remitting MS, she was treated with various MS disease-modifying therapies and eventually began experiencing secondary progression. At age 57 years, she developed an acute longitudinally extensive transverse myelitis and was found to have AQP4 antibodies by cell-based assay. Our analysis of the clinical course, radiographic findings, molecular diagnostic methods, and treatment response characteristics support the hypothesis that our patient most likely had 2 CNS inflammatory disorders: MS, which manifested as a teenager, and neuromyelitis optica spectrum disorder, which evolved in her sixth decade of life. This case emphasizes a key principle in neurology practice, which is to reconsider whether the original working diagnosis remains tenable, especially when confronted with evidence (clinical and/or paraclinical) that raises the possibility of a distinctively different disorder.
Glossary
- DMT=
- disease-modifying therapy;
- MS=
- multiple sclerosis;
- NMOSD=
- neuromyelitis optica spectrum disorder;
- RRMS=
- relapsing-remitting MS;
- S-1-P=
- sphingosine-1-phosphate;
- SPMS=
- secondary progressive MS;
- UTI=
- urinary tract infection
Footnotes
Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.
The Article Processing Charge was funded by the National Multiple Sclerosis Society.
Submitted and externally peer reviewed. The handling editor was Josep O. Dalmau, MD, PhD, FAAN.
- Received June 21, 2022.
- Accepted in final form August 12, 2022.
- Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Letters: Rapid online correspondence
- Author Response: Multiple Sclerosis Followed by Neuromyelitis Optica Spectrum Disorder
- Teresa C. Frohman, Author, Distinguished Senior Fellows (Sabbatical) Neuroimmunology Laboratory of Professor Lawrence Steinman, Stanford University School
- Steven L. Galetta, MD, Author, Departments of Neurology and Ophthalmology, New York University Grossman School of Medicine, New York, NY
- Robert Lisak, MD, Author, Department of Neurology, Wayne State University, Detroit MI
- Laura J. Balcer, MD, MSCE, Author, Departments of Neurology, Population Health, and Ophthalmology, New York University Grossman School of Medicine, New York, NY
- Michael K. Racke, MD, Author, Quest Diagnostics, 500 Plaza Drive, Secaucus, NJ
- Lawrence Steinman, MD, Author, Department of Neurology, Stanford University School of Medicine, Palo Alto, CA
- Scott S. Zamvil, Author, Department of Neurology and Program in Immunology, University of California San Francisco, San Francisco, California
- Elliot M. Frohman, Author, Distinguished Senior Fellows (Sabbatical) Neuroimmunology Laboratory of Professor Lawrence Steinman, Stanford University School
Submitted December 02, 2022 - Multiple Sclerosis Followed by Neuromyelitis Optica Spectrum Disorder
- robert laureno, neurologist, Georgetown University
Submitted November 29, 2022
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
- No related articles found.